RxDoctor Payments Data

John Franzese, MD

Gastroenterology · Chatham, NJNPI 1053390104

Payments from drug & device makers

$5,821in general payments, 2019–2025

Across 306 payments — averaging $19.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Olympus America Inc.$2K
  • AbbVie$1K
  • Bristol Myers Squibb$722
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$548
  • Takeda Pharmaceuticals U.S.A., Inc.$504
  • E.r. Squibb & Sons, L.L.C.$286
  • plus $698 from 15 others

What the payments were for

  • Consulting fees$150%
  • Food & beverage$4,17172%
  • Other$1,63528%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,821 in reported general payments places this provider in the 70th percentile of 701 gastroenterology providers in New Jersey.

See all gastroenterology providers in New Jersey

Medicare billing

Part B allowed, 2024
$213,696
Medicare patients
745
Services billed
1,686

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase59$127,984
LinzessLinaclotide62$62,609
Mesalamine55$44,667
XifaxanRifaximin11$23,119
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates338$22,162
TrulancePlecanatide24$19,886
ZenpepLipase/Protease/Amylase11$16,643
Dexlansoprazole DrDexlansoprazole34$14,280
Colesevelam Hcl20$9,855
Sucralfate25$6,481
CholestyramineCholestyramine (With Sugar)39$5,575
Famotidine285$4,688
SutabSod Sulf/Pot Chloride/Mag Sulf23$3,665
Lubiprostone19$3,040
Pantoprazole Sodium186$2,703

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$1,271$190,593121 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$548$43,00535 claims
Aimmune Therapeutics, Inc.Zenpep$48$16,64311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 701 gastroenterology providers in New Jersey.

Other gastroenterology in Chatham

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →